Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

6,481 total articles

Gartner at a Crossroads: Deep-Value Entry After the Big Deleveraging

Gartner at a Crossroads: Deep-Value Entry After the Big Deleveraging

Gartner (IT) has retraced sharply from a $451 52-week high to $158.65 today, trading at roughly $10.6B market cap with FCF of ~$1.26B and an EV/EBITDA near 8.5. That combination puts the stock in value territory and offers a tactical long opportunity for patient, risk-aware investors. The trade here is contingent on a stabilization in contract and …

Buy the Long View on Red Rock Resorts After Q1: Patience Over Pulses

Buy the Long View on Red Rock Resorts After Q1: Patience Over Pulses

Red Rock Resorts beat on earnings in Q1 driven by strong visitation and spend per visit, but revenue pressure and elevated costs keep the stock muted. At roughly $54.50 today, the stock offers a reasonable entry for a patient, long-term trade: attractive EV/EBITDA, solid free cash flow, and a track record of development-led growth. The trade is a d…

Global Partners - Favorable Valuation, Buy on Pullback (Rating Upgrade)

Global Partners - Favorable Valuation, Buy on Pullback (Rating Upgrade)

Global Partners (GLP) offers a rare blend of yield, free cash flow and reasonable valuation in a capital-intensive fuel-distribution business. At $48.75 the unit trades at an attractive P/FCF of 8.5 and EV/EBITDA of 8.9, with a 6%-plus yield and $193M in free cash flow backing distributions. We upgrade GLP and outline a mid-term (45 trading days) t…

CVS Health: Cheap, Improving Fundamentals and a Tactical Long Setup

CVS Health: Cheap, Improving Fundamentals and a Tactical Long Setup

CVS is trading near a fresh 52-week high after earnings and better-than-expected medical cost trends. Valuation metrics on a price-to-sales and EV basis remain attractive for a company with $7.4B in free cash flow and a meaningful dividend. This trade idea outlines a mid-term swing-long with entry at the market, a disciplined stop and a realistic t…

AMD: $700 Looks More Plausible Than $600 — A Long-Term Trade Idea

AMD: $700 Looks More Plausible Than $600 — A Long-Term Trade Idea

Advanced Micro Devices has ridden the AI wave to a dramatic rerating. With Q1 data-center growth at 57%, clean balance sheet metrics, and free cash flow of $8.57B, a $700 target inside 180 trading days is a reasonable bullish trade. This note lays out why $600 is likely too low, the valuation math, catalysts to watch, and a concrete trade plan with…

Novo Nordisk: Buy the Re-Rate as Wegovy Pill Rewrites Growth

Novo Nordisk: Buy the Re-Rate as Wegovy Pill Rewrites Growth

Novo Nordisk’s Q1 beat and the blockbuster uptake of the Wegovy pill give the stock room to re-rate. With reported Q1 sales of $15.17B, guidance raised to $42.39-$46.24B, and more than 2 million Wegovy prescriptions since launch, the company is pivoting from price-driven headwinds to volume-led growth. Valuation (market cap ~$209B, P/E ~10.8) leave…

Apple's Hidden AI Toll Booth: A Trade Idea on Capture and Cash Flow

Apple's Hidden AI Toll Booth: A Trade Idea on Capture and Cash Flow

Apple's device+services moat positions it to monetize AI in a uniquely high-margin way. With a $4.3T market cap, $129B of free cash flow and industry-leading returns on capital, the stock is richly priced but offers an asymmetric payoff if Apple converts AI features into recurring paid services. This trade is a long position sized for conviction wi…

Keysight: The Understated Backbone of the AI Infrastructure Buildout

Keysight: The Understated Backbone of the AI Infrastructure Buildout

Keysight supplies test, measurement and validation tools that data center, telecom and semiconductor customers need to deploy reliable AI hardware at scale. With AI-related revenue accelerating, strong free cash flow and a defensive defense/government business, Keysight offers a high-conviction swing trade. Valuation is rich, so execute with define…

Cerus: Q1 Follow-Through Makes a Convincing Case to Buy the Turnaround

Cerus: Q1 Follow-Through Makes a Convincing Case to Buy the Turnaround

Cerus (CERS) looks like a validated turnaround after recent results and follow-through in price and volume. The company still carries execution risk and a stretched valuation relative to profitability, but the combination of rising demand for INTERCEPT systems, a cleaner cash runway and a surge in short interest sets up a trade with asymmetric upsi…

Verizon Remains a Buy After Q1: Income, FCF, and 5G Momentum Intact

Verizon Remains a Buy After Q1: Income, FCF, and 5G Momentum Intact

Verizon is trading near $47 with a 5.9% yield, healthy free cash flow of $20.3B, and improving subscriber and EBITDA momentum. The stock looks attractively valued at ~11x earnings and ~7.5x EV/EBITDA. For income-focused traders who also want upside, a mid-term swing trade into $52.50 with a $44 stop provides a favorable risk/reward while preserving…

Buy Eli Lilly After Q1 Strength — Momentum Meets Durable Cash Flow

Buy Eli Lilly After Q1 Strength — Momentum Meets Durable Cash Flow

Eli Lilly reported explosive top-line and EPS growth driven by its GLP-1 franchise and pipeline momentum. With rumored incremental 2026 revenue upside, a clean safety profile on key non-GLP assets and free cash flow of roughly $11.8B, LLY looks set for further appreciation. This trade idea lays out a clear entry, stop and target across a position-l…

KRYS: Look Past VYJUVEK - The Pipeline Is the Real Growth Engine

KRYS: Look Past VYJUVEK - The Pipeline Is the Real Growth Engine

Krystal Biotech's marketed product VYJUVEK has put the company on the map and produced strong revenue in 2025, but investors are underpricing the optionality from multiple gene-therapy programs with near-term catalysts. With solid cash on the balance sheet, positive free cash flow, and a suite of presentations and readouts ahead, KRYS is a buy for …

Buying Dell Near the Top Feels Risky - Still Putting a Sliver to Work

Buying Dell Near the Top Feels Risky - Still Putting a Sliver to Work

Dell is trading near its 52-week high after a big gap higher, driven by AI supercomputer deals and improving ISG dynamics. Valuation is full by several measures and momentum is stretched, but cash generation ($8.55B FCF) and meaningful enterprise exposure make a scaled, risk-defined long sensible for a swing trade. Entry $255, stop $235, target $30…

Nutrien: Underpriced Exposure to a Structural Fertilizer Shortage

Nutrien: Underpriced Exposure to a Structural Fertilizer Shortage

Nutrien (NTR) is a high-quality crop nutrient platform trading at a modest P/E and a 3.2% yield while sitting squarely in the path of a global fertilizer supply squeeze. The market is discounting Fertilizer cyclicality more than the durable demand drivers, creating an asymmetric trade - income today and meaningful upside if supply dynamics persist.

MongoDB Setup: Atlas Momentum + AI Demand = Tactical Long Into Earnings

MongoDB Setup: Atlas Momentum + AI Demand = Tactical Long Into Earnings

MongoDB's Atlas product and growing AI workloads keep the growth narrative intact despite recent volatility. Technical momentum, improving free cash flow ($500M), and a valuation that prices future growth create a tactical long setup into upcoming catalysts. Trade plan with entry at $300, stop at $275, target $380 for a mid-term (45 trading days) h…